What's new? Log in Free sign up

Clearside Biomedical (CLSD) News and press releases

Company Profile

News

From Benzinga Pro

Stocks That Hit 52-Week Lows On Tuesday

During Tuesday, 95 stocks hit new 52-week lows.

12 Health Care Stocks Moving In Friday's After-Market Session

Stocks That Hit 52-Week Lows On Thursday

Thursday's session saw 337 companies set new 52-week lows.

What 5 Analyst Ratings Have To Say About Clearside Biomedical

Analyst Ratings

JMP Securities Maintains Market Outperform on Clearside Biomedical, Lowers Price Target to $6

News, Price Target, Analyst Ratings

JMP Securities analyst Jonathan Wolleben maintains Clearside Biomedical (NASDAQ:CLSD) with a Market Outperform and lowers the price target from $7 to $6.

United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday

News, Penny Stocks, Price Target, Small Cap, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas

Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to $5.51 in pre-market trading.

HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $6 price target.

Needham Maintains Buy on Clearside Biomedical, Lowers Price Target to $4

News, Price Target, Analyst Ratings

Needham analyst Serge Belanger maintains Clearside Biomedical (NASDAQ:CLSD) with a Buy and lowers the price target from $5 to $4.

Clearside Biomedical Q4 EPS $(0.16) Misses $(0.13) Estimate, Sales $330.00K Beat $100.00K Estimate

Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 151.61 percent decrease over earnings of $0.31 per

Earnings Scheduled For March 9, 2023

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.

A Preview Of Clearside Biomedical's Earnings

JMP Securities Reiterates Market Outperform on Clearside Biomedical, Maintains $7 Price Target

News, Price Target, Reiteration, Analyst Ratings

JMP Securities analyst Jonathan Wolleben reiterates Clearside Biomedical (NASDAQ:CLSD) with a Market Outperform and maintains $7 price target.

Analyst Expectations for Clearside Biomedical's Future

Analyst Ratings

Needham Reiterates Buy on Clearside Biomedical, Maintains $5 Price Target

News, Price Target, Reiteration, Analyst Ratings

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $5 price target.

Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder

Biotech, News, Penny Stocks, Health Care, Movers, General

Clearside Biomedical Inc (NASDAQ: CLSD) announced results from the Extension Study of its OASIS Phase 1/2a trial of CLS-AX (axitinib) administered by suprachoroidal injection via SCS Microinjector in neovascular age-related macular degeneration participants.

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Press releases

From Benzinga Pro

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

News, Press Releases

ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

News, Press Releases

- CLS-AX OASIS Results Show Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - SCS Microinjector® Featured in Favorable Data Presentations

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

News, Press Releases

ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space

Clearside Biomedical Announces Leadership Team Update

ALPHARETTA, Ga., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Health Care, Press Releases

- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went at Least 6 Months

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.